UK volunteers are being recruited for a phase 1 trial of a potential vaccine designed to combat the Bundibugyo strain of Ebola, in a rapid response to the ongoing outbreak in central Africa. Developed in just eight weeks at Oxford University, the ChAdOx1 BDBV vaccine uses the same technology platform as the Oxford-AstraZeneca Covid-19 vaccine. The trial has received conditional regulatory approval from the UK Medicines and Healthcare Products Regulatory Agency and will assess safety and immune response in 50 healthy adults aged 18 to 55. BMJ report ([bmj.com](https://www.bmj.com/content/394/bmj-2026-100286?utm_source=openai))
A fast-tracked response to a rare Ebola strain
The candidate vaccine is the first of four against the Bundibugyo strain to enter clinical trials, according to the BMJ report published on 14 July 2026. Scientists moved quickly after the outbreak intensified, with the goal of having a potential jab ready for testing in a matter of weeks rather than months. Vaccinations are expected to begin after full regulatory approval, while production has already started. ([bmj.com](https://www.bmj.com/content/394/bmj-2026-100286?utm_source=openai))
Why the trial matters for public health
The Bundibugyo strain has drawn heightened attention because current countermeasures are limited. The BMJ noted that the trial comes in response to the ongoing outbreak in central Africa, where researchers and health agencies have been pushing to accelerate vaccine and treatment development. The move adds to a wider international effort to strengthen preparedness for Ebola outbreaks and improve options for both frontline health workers and at-risk communities. ([bmj.com](https://www.bmj.com/content/394/bmj-2026-100286?utm_source=openai))
In the UK, the study will be closely watched not only for what it may reveal about the new vaccine, but also for what it could mean for future outbreak response planning. If the vaccine proves safe and capable of generating an immune response, it could become an important tool in efforts to control a strain that has prompted urgent global health action. ([bmj.com](https://www.bmj.com/content/394/bmj-2026-100286?utm_source=openai))
